CN Patent

CN111825717A — 5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的晶形

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2020-10-27 · 6y expired

What this patent protects

本申请涉及5‑氯‑N4‑[2‑(二甲基磷酰基)苯基]‑N2‑{2‑甲氧基‑4‑[4‑(4‑甲基哌嗪‑1‑基)哌啶‑1‑基]苯基}嘧啶‑2,4‑二胺的晶形。本文公开了布格替尼的晶形、包含布格替尼的晶形的药物组合物及它们的制备和使用方法。

USPTO Abstract

本申请涉及5‑氯‑N4‑[2‑(二甲基磷酰基)苯基]‑N2‑{2‑甲氧基‑4‑[4‑(4‑甲基哌嗪‑1‑基)哌啶‑1‑基]苯基}嘧啶‑2,4‑二胺的晶形。本文公开了布格替尼的晶形、包含布格替尼的晶形的药物组合物及它们的制备和使用方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN111825717A
Jurisdiction
CN
Classification
—
Expires
2020-10-27
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.